Rapport Therapeutics, Inc. (RAPP)
NASDAQ:RAPP
Total Valuation
Rapport Therapeutics, Inc. has a market cap or net worth of $1.60B. The enterprise value is $1.18B.
Market Cap$1.60B
Enterprise Value$1.18B
Share Statistics
Rapport Therapeutics, Inc. has 47,792,942 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding47,792,942
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rapport Therapeutics, Inc.’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -25.21%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-25.21%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee0.00
Profits Per Employee-1.62M
Employee Count69
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rapport Therapeutics, Inc. is ―. Rapport Therapeutics, Inc.’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.94
Price to Fair Value2.94
Price to FCF-16.18
Price to Operating Cash Flow-18.03
PEG Ratio-0.02
Income Statement
In the last 12 months, Rapport Therapeutics, Inc. had revenue of 0.00 and earned -111.48M in profits. Earnings per share was -2.86.
Revenue0.00
Gross Profit-1.02M
Operating Income-125.10M
Pretax Income-111.48M
Net Income-111.48M
EBITDA-124.08M
Earnings Per Share (EPS)-2.86
Cash Flow
In the last 12 months, operating cash flow was -87.47M and capital expenditures -447.00K, giving a free cash flow of -87.92M billion.
Operating Cash Flow-87.47M
Free Cash Flow-87.92M
Free Cash Flow per Share-1.84
Dividends & Yields
Rapport Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change294.13%
50-Day Moving Average28.31
200-Day Moving Average23.87
Relative Strength Index (RSI)63.33
Average Volume (3m)341.95K
Important Dates
Rapport Therapeutics, Inc. upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Rapport Therapeutics, Inc. as a current ratio of 26.17, with Debt / Equity ratio of 2.37%
Current Ratio26.17
Quick Ratio26.17
Debt to Market Cap<0.01
Net Debt to EBITDA0.33
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Rapport Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Rapport Therapeutics, Inc. EV to EBITDA ratio is -11.16, with an EV/FCF ratio of -15.71.
EV to Sales0.00
EV to EBITDA-11.16
EV to Free Cash Flow-15.71
EV to Operating Cash Flow-15.82
Balance Sheet
Rapport Therapeutics, Inc. has $490.54M in cash and marketable securities with $11.48M in debt, giving a net cash position of $479.06M billion.
Cash & Marketable Securities$490.54M
Total Debt$11.48M
Net Cash$479.06M
Net Cash Per Share$10.02
Tangible Book Value Per Share$10.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rapport Therapeutics, Inc. is $47.80, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$47.80
Price Target Upside42.35% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-37.07%